Chad M Robins Adaptive Biotechnologies Corp (ADPT) insider trading activity

Chad M Robins is CEO and Chairman of Adaptive Biotechnologies Corp. Currently has a direct ownership of 2.96 Million shares of ADPT, which is worth approximately $21.8 Million. The most recent transaction as insider was on Mar 06, 2025, when has been sold 102,218 shares (Common Stock) at a price of $7.64 per share, resulting in proceeds of $780,945. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.96M

14.85% 3M change

14.85% 12M change

Total Value Held $21.8 Million

CHAD M ROBINS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 06 2025	SELL Open market or private sale	$780,945 $7.64 p/Share	102,218 Reduced 3.34%	2,959,249 Common Stock
Mar 05 2025	SELL Open market or private sale	$820,283 $6.99 p/Share	117,351 Reduced 4.0%	2,814,350 Common Stock
Mar 05 2025	BUY Grant, award, or other acquisition	-	247,117 Added 7.47%	3,061,467 Common Stock
Mar 04 2025	BUY Grant, award, or other acquisition	-	355,000 Added 10.8%	2,931,701 Common Stock
Feb 20 2025	SELL Open market or private sale	$836,463 $8.44 p/Share	99,107 Reduced 3.7%	2,576,701 Common Stock
Feb 20 2025	BUY Exercise of conversion of derivative security	$626,356 $6.32 p/Share	99,107 Added 3.57%	2,675,808 Common Stock
Feb 19 2025	SELL Open market or private sale	$1,574,236 $8.46 p/Share	186,080 Reduced 6.74%	2,576,701 Common Stock
Feb 19 2025	BUY Exercise of conversion of derivative security	$1,176,025 $6.32 p/Share	186,080 Added 6.31%	2,762,781 Common Stock
Feb 18 2025	SELL Open market or private sale	$1,794,860 $8.5 p/Share	211,160 Reduced 7.57%	2,576,701 Common Stock
Feb 18 2025	BUY Exercise of conversion of derivative security	$1,334,531 $6.32 p/Share	211,160 Added 7.04%	2,787,861 Common Stock
Feb 14 2025	SELL Open market or private sale	$1,344,471 $8.46 p/Share	158,921 Reduced 5.81%	2,576,701 Common Stock
Feb 14 2025	BUY Exercise of conversion of derivative security	$1,004,380 $6.32 p/Share	158,921 Added 5.49%	2,735,622 Common Stock
Feb 13 2025	SELL Open market or private sale	$846,422 $8.44 p/Share	100,287 Reduced 3.75%	2,576,701 Common Stock
Feb 13 2025	BUY Exercise of conversion of derivative security	$633,813 $6.32 p/Share	100,287 Added 3.61%	2,676,988 Common Stock
Mar 05 2024	SELL Open market or private sale	$167,435 $3.44 p/Share	48,673 Reduced 1.85%	2,576,701 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	354,610 Added 11.9%	2,625,374 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	354,610 Added 13.51%	2,270,764 Common Stock
Mar 09 2022	SELL Exercise of conversion of derivative security	$93,631 $6.32 p/Share	14,815 Reduced 0.76%	1,930,969 Common Stock
Mar 09 2022	SELL Open market or private sale	$184,595 $12.46 p/Share	14,815 Reduced 0.77%	1,916,154 Common Stock
Mar 08 2022	SELL Exercise of conversion of derivative security	$93,631 $6.32 p/Share	14,815 Reduced 0.76%	1,930,969 Common Stock
Mar 08 2022	SELL Open market or private sale	$168,595 $11.38 p/Share	14,815 Reduced 0.77%	1,916,154 Common Stock
Mar 07 2022	SELL Open market or private sale	$176,002 $11.88 p/Share	14,815 Reduced 0.77%	1,916,154 Common Stock
Mar 07 2022	SELL Open market or private sale	$53,132 $12.01 p/Share	4,424 Reduced 0.23%	1,916,154 Common Stock
Mar 07 2022	BUY Exercise of conversion of derivative security	$93,631 $6.32 p/Share	14,815 Added 0.76%	1,930,969 Common Stock
Mar 04 2022	BUY Grant, award, or other acquisition	-	247,117 Added 11.4%	1,920,578 Common Stock

CMR

Chad M Robins

CEO and Chairman

Seattle, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Value

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT

Account